Overview
Braveheart Bio Inc. saw its shares climb sharply on the first day of trading in New York, finishing up 68% after the firm completed a $382.5 million initial public offering in the United States. The stock opened at $30.20 per share, significantly above the IPO price of $18, and the company’s market value reached approximately $2.13 billion based on outstanding shares.
Business focus and licensing
Founded in 2024, Braveheart is a clinical-stage biopharmaceutical company whose lead candidate is BHB-1893. That asset is being developed to treat hypertrophic cardiomyopathy, an inherited condition that impairs the heart’s ability to pump blood. Braveheart obtained the licensing rights to BHB-1893 from Jiangsu Hengrui Pharmaceuticals, a Chinese drugmaker.
Financing and investors
Prior to and alongside the IPO, the company has raised roughly $185 million from institutional investors, including Andreessen Horowitz’s biotech fund and Patient Square Capital. The company’s governance includes Christopher Viehbacher - who serves as chief executive officer of Biogen Inc. - in the role of chairman at Braveheart.
Recent financials
Braveheart reported a net loss of $14.3 million and generated about $11 million in revenue during the first quarter of 2026. By comparison, the company recorded a net loss of $99,000 in the same period of 2025.
Underwriters and listing
The initial public offering was underwritten by Goldman Sachs Group Inc., Jefferies Financial Group Inc., Toronto-Dominion Bank, Stifel Financial Corp., and Cantor Fitzgerald. Braveheart Bio now trades on the Nasdaq Global Market under the ticker symbol BRVE.
Market context
The stock’s opening price and first-day increase reflect market demand for the listing, while the company remains a clinical-stage developer with recent losses and modest revenue. The completion of the $382.5 million IPO provides additional capital as Braveheart advances its lead program, which was licensed from Jiangsu Hengrui Pharmaceuticals.